Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Efficacy and Safety Data of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in Heavily Pretreated Patient Population Announced

December 4, 2023

Imfinzi + Avastin met primary endpoint for PFS in liver cancer eligible for embolisation in EMERALD-1 Ph 3 trial

December 4, 2023

KEYTRUDA Significantly Improved OS Versus Placebo as Adjuvant Therapy for Certain Patients With RCC Following Nephrectomy

November 7, 2023

Ph 3 RUBY trial of Jemperli + chemotherapy meets OS endpoint in patients with primary advanced or recurrent endometrial cancer

November 7, 2023

Initial Ph 2 Data on Personalized Cancer Vaccine EVX-01 Announced

November 7, 2023

Ph 3 CheckMate-67T Trial of SC Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced/Metastatic ccRCC

October 25, 2023

New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study Released

October 25, 2023

Interim PK/PD and Clinical Data for MRT-2359 in Ph 1/2 Trial for MYC-Driven Solid Tumors announced

October 25, 2023

Positive Initial Topline Ph 2a Data of SLS009 in AML announced

October 25, 2023

New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized 1L HCC Study presented

October 16, 2023

Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of OS in Resectable Stage II, IIIA or IIIB NSCLC

October 16, 2023

Updated PC14586 Ph 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation

October 16, 2023

Positive BEXMAB Study Update in R/R AML and HMA-Refractory MDS Patients Announced

October 16, 2023

Interim Results from Ph 2 Trial of IT LSAM-PTX in Locally Advanced Pancreatic Cancer Patients Announced

October 16, 2023

Interim Safety and Immune Response Data from Ph 1/2 Trial of PDS0301 + Docetaxel in Metastatic Prostate Cancer announced

October 16, 2023

Data from two ongoing clinical studies with NUC-3373 in CRC announced

October 16, 2023

Positive Preliminary Data from Ph 1 Dose Escalation Portion of Ph 1/2 KB-0742 Study presented

October 16, 2023

Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors announced

October 16, 2023

Positive Interim Ph 2 ASPEN-06 Trial Results of Evorpacept in Advanced HER2+ve Gastric Cancer Reported

October 11, 2023

KEYTRUDA® Met Primary Endpoint of DFS in Certain Patients With Muscle-Invasive Urothelial Carcinoma (MIUC) After Surgery

October 11, 2023

Promising Readout from Ph 2a Trial of BPM 31510 IV for Pancreatic Cancer Announced

October 11, 2023

Ph 3 MARIPOSA Study Meets Primary Endpoint of PFS for RYBREVANT  (amivantamab-vmjw) + Lazertinib vs Osimertinib in EGFR-Mutated NSCLC

October 3, 2023

FAILED TRIAL: Ph 3 CANOVA Study of Venetoclax in Patients with RRMM failed to meet primary endpoint of PFS improvement

October 3, 2023

Positive Clinical Data in Pancreatic Cancer and SCLC, including Single-Agent Activity from Onvansertib Monotherapy

October 3, 2023

Updated Clinical Data for FasTCAR-T GC012F for High-Risk, Newly Diagnosed Multiple Myeloma, Demonstrating 100% Stringent CRR reported

October 3, 2023
Page1 … Page15 Page16 Page17 Page18 Page19 … Page29

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.